Abstracts tagged "Disease Activity"

Abstract Number: 0634 • ACR Convergence 2024
Clinical Relevance of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) in Predicting Lupus Outcomes: A 5-Year Longitudinal Cohort Study
Hyemin Jeong¹, Ji-Hyoun Kang¹, Sung-Eun Choi², Dong-Jin Park³ and Shin-Seok Lee⁴, ¹Chonnam National University Hospital, Gwangju, South Korea, ²Chonnam National University Medical School & Hospital, Gwangju, South Korea, ³Chonnam National University Medical School and Hospital, Gwangju, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) is a newly developed tool for assessing disease activity in SLE patients. Despite external validation in diverse…
Abstract Number: 0872 • ACR Convergence 2024
Investigating the Natural Improvement of Rheumatoid Arthritis During Pregnancy
Matthew Wright¹, Dana Goin², Mette Kiel Smed³, Nicholas Jewell⁴, J Lee Nelson⁵, Merete Hetland⁶ and Damini Jawaheer⁷, ¹Children's Hospital Oakland Research Institute/Northwestern University, Chicago, ²UCSF, San Francisco, CA, ³Juliane Marie Centret, Copenhagen, Denmark, ⁴UC Berkeley, Berkeley, CA, ⁵University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, ⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁷Children's Hospital Oakland Research Institute/Northwestern University, Chicago, IL
Background/Purpose: Pregnancy can induce a natural improvement of rheumatoid arthritis (RA) in 50-75% of women with the disease, while others may worsen or remain unchanged.…
Abstract Number: 1332 • ACR Convergence 2024
Financial Distress and Its Determinants in Adults with Rheumatoid Arthritis
Amber Brown Keebler¹, Yunju Im², Sofia Pedro³, Ted Mikuls¹, Edward Peters¹ and Kaleb Michaud¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, ³Forward, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Often not evaluated in clinical visits, financial distress associated with medical costs, also known as financial toxicity, has emerged as an important factor affecting…
Abstract Number: 1382 • ACR Convergence 2024
Synovial Expression Levels of PD-1, the Target of Rosnilimab, Correlate with Disease Activity and Persist Across Disease Stages and Lines of Therapy in Rheumatoid Arthritis
Yangsu Ren¹, Catherine Aversa¹, Myles Lewis², Cankut Cubuk³, Felice Rivellese⁴, Liliane Fossati-Jimack³, Pejman Soroosh¹, Amy Archer¹, Martin Dahl¹, Paul Lizzul¹, Cailin Sibley¹ and Costantino Pitzalis⁵, ¹AnaptysBio, San Diego, CA, ²Queen Mary University of London, London, United Kingdom, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London and Barts NIHR BRC & NHS Trust, London, EC1M 6BQ, London, United Kingdom, ⁴Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ⁵QMUL, Bromley Kent, United Kingdom
Background/Purpose: Despite multiple approved therapies in rheumatoid arthritis (RA), many patients do not achieve clinically meaningful responses, emphasizing the need for novel therapeutics with improved…
Abstract Number: 1605 • ACR Convergence 2024
Characteristics of Relapses in Patients with Eosinophilic Granulomatosis with Polyangiitis
Peter Merkel¹, David Jayne², Ulrich Specks³, Christian Pagnoux⁴, Parameswaran Nair⁵, Nader Khalidi⁵, Arnaud Bourdin⁶, Lena Börjesson Sjö⁷, Sofia Necander⁷, Anat Shavit⁸, Claire Walton⁹ and Michael Wechsler¹⁰, ¹University of Pennsylvania, Philadelphia, PA, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁶Department of Respiratory Diseases, University of Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, France, ⁷Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁸BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁰National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis. In the Phase 3, double-blind,…
Abstract Number: 1968 • ACR Convergence 2024
Development and Validation of an Arthritis-Detection Algorithm Using Thermal Imaging in Adults and Children
Thomason Jenna¹, Sullivan Erin², Rajdeep Pooni³, Liau Adriel⁴, Sadie Van den Bogaerde⁵, Audrey Luey⁶, Iris Hamilton⁷, Sriya Paluvayi⁶, Megan Tran¹, Janeth Robles-Navarro¹, Ian Muse⁸, Ava Klein⁴, Tzielan Lee⁹, Grant Hughes⁵, Alison Bays⁵, Elizabeth Ferucci¹⁰, Debosmita Biswas¹¹, Savannah Patridge¹¹ and Yongdong (Dan) Zhao¹², ¹University of Washington, Division of Rheumatology, Seattle, WA, ²Biostatistics, Epidemiology, and Analytics in Research (BEAR) Core, Seattle Children’s Research Institute, Seattle, WA, ³Stanford University, Palo Alto, CA, ⁴Seattle Children’s Research Institute, University of Washington, Seattle, ⁵University of Washington, Seattle, WA, ⁶Seattle Children’s Research Institute, University of Washington, Seattle, WA, ⁷Seattle Children's Hospital, Seattle, ⁸Seattle Children's Research institute, Seattle, WA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Alaska Native Tribal Health Consortium, Anchorage, AK, ¹¹University of Washington, Department of Radiology, Seattle, WA, ¹²University of Washington, Redmond, WA
Background/Purpose: The Thermal imaging-based Temperature After Within-limb Calibration (TAWiC) algorithm for the detection of arthritis in the knees has been validated in children by our…
Abstract Number: 2268 • ACR Convergence 2024
The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Bindee Kuriya³, Sibel Aydin⁴, Claire Bombardier⁵ and Pooneh Seyed-Akhavan⁶, and OBRI investigators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²UHN, Toronto, ON, Canada, ³University of Toronto - Toronto, Toronto, ON, Canada, ⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Sinai Health System, Toronto, ON, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) who fail conventional synthetic treatment with disease modifying anti-rheumatic drugs (csDMARDs) are eligible for biological DMARDs (bDMARDs) or targeted…
Abstract Number: 2426 • ACR Convergence 2024
Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
Michaela Koehm¹, Samuel Rischke², Robert Gurke³, Gerd Geißlinger⁴ and Frank Behrens¹, ¹University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Goethe University Frankfurt, Institute of Clinical Pharmacology, Frankfurt, Germany, ³Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁴Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a very heterogeneous clinical presentation and severity. Despite the variety of treatment options available,…
Abstract Number: 0334 • ACR Convergence 2024
Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
shiri keret¹, Tanya Chandra², Lisa Kaly³, Raisa Silva⁴, Eugenia Gkiaouraki⁵, Nantakarn Pongtarakulpanit⁶, shreya Sriram⁵, Rajesh Gopalarathinam⁷, Siamak Mogahadam⁶, Chester Oddis⁶ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, PA, ³Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Haifa, Israel, ⁴Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Creatine kinase (CK) is an important biomarker for the diagnosis and monitoring of Idiopathic Inflammatory Myopathies (IIM). However, in some cases, CK levels might…
Abstract Number: 0551 • ACR Convergence 2024
Evaluation of Instruments Assessing Peripheral Arthritis in Spondyloarthritis: An Analysis of the ASAS-perSpA Study
Dafne Capelusnik¹, Anna Molto², Clementina López Medina³, Desiree van der Heijde⁴, Robert Landewé⁵, Maxime Dougados⁶, Joachim Sieper⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Reina Sofia University Hospital, Cordoba, Spain, ⁴Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁵Amsterdam University Medical Center, Meerssen, Netherlands, ⁶Rheumatology Department, Cochin Hospital and Clinical Epidemiology and Biostatistics, University of Paris, INSERM (U1153), Paris, France, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The optimal instrument to assess peripheral arthritis and related disease activity in SpA has not yet been identified. In the recent update of the…
Abstract Number: 0638 • ACR Convergence 2024
Soluble TNF RII in Lupus Nephritis as a Biomarker of Disease Activity and Treatment Response
Ranjan Gupta¹, Sonam Rajput², Jayanth Kumar² and Dipendra K Mitra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, New Delhi, India
Background/Purpose: Lupus Nephritis (LN) affects almost 60-70% patients of Systemic Lupus Erythematosus (SLE). Conventional markers of renal involvement i.e. proteinuria and renal biopsy have limitations…
Abstract Number: 1000 • ACR Convergence 2024
Adalimumab Biosimilar-to-biosimilar Switch in Patients with Inflammatory Rheumatic Diseases – Real-world Evidence from the Nationwide Danish Registry, DANBIO
Kasper Yde Jensen¹, Hafsah Nabi², Dorte Vendelbo Jensen³, Jens Pedersen⁴, Oliver Hendricks⁵, Anne Gitte Loft⁶, Ada Colic⁷, Kamilla Danebod³, Salome Kristensen⁸, Heidi Munk⁹, Niels Lomborg¹⁰, Natalia Manilo¹¹, Stavros Chrysidis¹², Søren Just¹³, Asta Linauskas¹⁴, Pil Højgaard¹⁵, Pia Høger Thygesen¹⁶, Malene Kildemand¹⁷, Rene Drage Oestgaard¹⁸, Merete Hetland¹⁹ and Bente Glintborg²⁰, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, Glostrup, Denmark, ³Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark, ⁴Department of Rheumatology C, Research Unit, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark, ⁵Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, ⁶Department of Rheumatology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark, ⁷Department of Rheumatology, Zealand University Hospital, Koege, Denmark, ⁸Centre of Rheumatic Research Aalborg, Department of Rheumatology and Aalborg University Hospital and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁹Department of Rheumatology, Odense University Hospital, Odense, Denmark and Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁰Department of Rheumatology, Vejle Hospital Lillebælt, Odense C, Denmark, ¹¹Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, ¹²Department of Rheumatology, University Hospital of Southern Denmark, Esbjerg, Denmark, ¹³Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, ¹⁴Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ¹⁵Department of Internal Medicine 2; Rheumatology, Holbæk Sygehus, Holbæk, Denmark and Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Frederiksberg Hospital, Copenhagen, Denmark, ¹⁶Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, ¹⁷Department of Rheumatology, Odense University Hospital, Svendborg, Denmark, ¹⁸Department of Medicine, Goedstrup Regional Hospital and Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ²⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In Denmark, mandatory switches between originators and corresponding biosimilar products have been performed for economic reasons for nearly a decade (1). Starting in January…
Abstract Number: 1333 • ACR Convergence 2024
Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study
Orit Schieir¹, Marie-France Valois², Gilles Boire³, Louis Bessette⁴, Carter Thorne⁵, Susan Bartlett², Glen Hazlewood⁶, Carol Hitchon⁷, Diane Tin⁵, Hugues Allard-Chamard⁸, Bindee Kuriya⁹, Janet Pope¹⁰ and Vivian Bykerk¹¹, and on behalf of CATCH Investigators, ¹McGill University, Montreal, QC, Canada, ²Centre for Outcomes Research & Eval, Montreal, QC, Canada, ³Retired, Sherbrooke, QC, Canada, ⁴University of Laval, Quebec City, QC, Canada, ⁵Newmarket Rheumatology Consultants, Newmarket, ON, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Sherbrooke, Sherbrooke, QC, Canada, ⁹University of Toronto, Toronto, Canada, ¹⁰University of Western Ontario, London, ON, Canada, ¹¹Hospital For Special Surgery, New York, NY
Background/Purpose: Despite advances in early RA diagnosis and therapies, treatment outcomes can still vary considerably. Our objective was to compare short and long-term disease control…
Abstract Number: 1390 • ACR Convergence 2024
One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Luis Gomez-Lechon Quiros¹, José Miguel Sequí-Sabater², Amalia Rueda³, Costas Torrijo Nerea⁴, Carlos Valera-Ribera⁵, Juan Miguel López-Gómez⁶ and Antonio Alvarez-Cienfuegos⁷, ¹Hospital Francesc de Borja, Valéncia, Spain, ²La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, ³Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ⁴Generalitat valenciana, Valencia, Spain, ⁵Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ⁶Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, ⁷Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
Abstract Number: 1615 • ACR Convergence 2024
Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
Fatih Yildirim¹, Cemal Bes², Muhammet Emin Kutu³, Fatih Tastekin⁴, Gokhan Keser⁵, Tugba Ocak⁶, Ediz Dalkilic⁶, Yavuz Pehlivan⁶, Hasan Kocaayan⁷, Servet Akar⁷, Sema İsik⁸, Ahmet Omma⁹, Senar San¹⁰, Ayten Yazici¹¹, Ayse Cefle¹¹, Safiye Bakkal¹², Gökçe Kenar¹³, Fatos Onen¹², Aysegül Avcu¹⁴, Fatma Alibaz Öner¹⁵, Haner Direskeneli¹⁵, Burcu Ceren Uludogan¹⁶, Nazife Sule yaşar Bile¹⁶ and Nilüfer Alpay Kanıtez¹⁷, ¹University of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ²University of Health Sciences Başakşehir Çam and Sakura City HospitalUniversity of Health Sciences Başakşehir Çam and Sakura City Hospital, İstanbul, Turkey, İstanbul, Turkey, ³Bakirkoy Dr Sadi Konuk Training and Research Hospital, Istanbul, Turkey, ⁴Ege University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁵Ege University School of Medicine, Rheumatology, İzmir, Turkey, Izmir, Turkey, ⁶Uludağ University Faculty of Medicine, Rheumatology, Bursa, Turkey, Bursa, Turkey, ⁷İzmir Katip Celebi University School of Medicine, Rheumatology, İzmir, Turkey, İzmir, Turkey, ⁸University of Health Sciences Ankara Bilkent City Hospital, Rheumatology, Ankara, Turkey, Ankara, Turkey, ⁹Ankara Bilkent City Hospital, Ankara, Turkey, ¹⁰Kocaeli University Faculty of Medicine, Rheumatology, Kocaeli, Turkey, Kocaeli, Turkey, ¹¹Kocaeli University Faculty of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, ¹²Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, İzmir, Turkey, ¹³Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁴Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, İstanbul, Turkey, ¹⁵Marmara University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey, ¹⁶Osmangazi University Faculty of Medicine, Rheumatology, Eskişehir, Turkey, Eskisehir, Turkey, ¹⁷Koc University Faculty of Medicine, Rheumatology, İstanbul, Turkey, Istanbul, Turkey
Background/Purpose: The understanding of progression or minimal disease activity in patients with Takayasu arteritis (TA) can be complicated due to the possibility of mild vascular…

« Previous Page
1
…
5
6
7
8
9
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].